Astrocytes and neurons: Different roles in regulating adenosine levels

Neurological Research

Volumn 27, Issue 2, 2005, Pages 153-160

  Parkinson, Fiona E ^a   Xiong, Wei ^a   Zamzow, Christina R ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

5 Nucleotidase; Adenosine; Inosine; Nucleoside transport

Indexed keywords

ADENOSINE; DIPYRIDAMOLE; ECTO 5' NUCLEOTIDASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; INOSINE; NUCLEOSIDE; S ADENOSYLHOMOCYSTEINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTE; BRAIN ISCHEMIA; CELL TYPE; CONTROLLED STUDY; DEPHOSPHORYLATION; ENZYME ACTIVITY; EVOKED RESPONSE; NERVE CELL CULTURE; NERVE FUNCTION; NERVE INJURY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEOSIDE TRANSPORT; RAT; REVIEW; SEIZURE; STROKE; SYNAPTIC TRANSMISSION;

ADENOSINE; AFFINITY LABELS; ANIMALS; ANOXIA; ASTROCYTES; BRAIN ISCHEMIA; CELLS, CULTURED; DEOXYGLUCOSE; DIPYRIDAMOLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLUCOSE; INOSINE; MODELS, BIOLOGICAL; NEURONS; OLIGOMYCINS; PHOSPHODIESTERASE INHIBITORS; PROSENCEPHALON; PURINES; RATS; THIOINOSINE; TRITIUM;

EID: 15244341323     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X21878     Document Type: Review

References (59)

1. Phillis JW, Wu PH. The role of adenosine and its nucleotides in central synaptic transmission. Prog Neurobiol 1981; 16: 187-239
2. Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 2001; 79: 463-484
3. Latini S, Corsi C, Pedata F, et al. The source of brain adenosine outflow during ischemia and electrical stimulation. Neurochem Int 1995; 27: 239-244
4. Todorov LD, Mihaylova Todorova S, et al. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature 1997; 387: 76-79
5. Zimmermann H. Signaling via ATP in the nervous system. Trends Neurosci 1994; 17: 420-426
6. Ruiz MA, Escriche M, Lluis C, et al. Adenosine A(1) receptor in cultured neurons from rat cerebral cortex: colocalization with adenosine deaminase. J Neurochem 2000; 75: 656-664
7. Baldwin SA, Beal PR, Yao SY, et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735-743
8. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447: 728-734
9. 3H]formycin B via sodium-dependent nucleoside transporters in mouse leukemic L1210/MA27.1 cells. J Pharmacol Exp Ther 1997; 281: 347-353
10. Newby AC, Worku Y, Holmquist CA. Adenosine formation. Evidence for a direct biochemical link with energy metabolism. Adv Myocardiol 1985; 6: 273-284
11. Rudolphi KA, Schubert P, Parkinson FE, et al. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 1992; 13: 439-445
12. Winn HR, Rubio GR, Berne RM. The role of adenosine in the regulation of cerebral blood flow. J Cereb Blood Flow Metab 1981; 1: 239-244
13. Berne RM, Winn HR, Rubio R. The local regulation of cerebral blood flow. Prog Cardiovasc Dis 1981; 24: 243-260
14. Masino SA, Dunwiddie TV. Temperature-dependent modulation of excitatory transmission in hippocampal slices is mediated by extracellular adenosine. J Neurosci 1999; 19: 1932-1939
15. Fredholm BB. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995; 76: 93-101
16. Chen JF, Huang Z, Ma J, et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192-9200
17. Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003; 64: 785-795
18. Meghji P, Newby AC. Sites of adenosine formation, action and inactivation in the brain. Neurochem Int 1990; 16: 227-232
19. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Ann Rev Neurosci 2001; 24: 31-55
20. Abraham EH, Prat AG, Gerweck L, et al. The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci USA 1993; 90: 312-316
21. Cotrina ML, Lin JHC, Alves-Rodrigues A, et al. Connexins regulate calcium signaling by controlling ATP release. Proc Natl Acad Sci USA 1998; 95: 15735-15740
22. Wang Y, Roman R, Lidofsky SD, et al. Autocrine signaling through ATP release represents a novel mechanism for cell volume regulation. Proc Natl Acad Sci USA 1996; 93: 12020-12025
23. Anderson CM, Bergher JP, Swanson RA. ATP-induced ATP release from astrocytes. J Neurochem 2004; 88: 246-256
24. Darby M, Kuzmiski JB, Panenka W, et al. ATP released from astrocytes during swelling activates chloride channels. J Neurophysiol 2003; 89: 1870-1877
25. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276: 33747-33754
26. van Aubel RA, Smeets PH, Peters JG, et al. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13: 595-603
27. Rosenberg PA, Li Y. Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by β-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Brain Res 1995; 692: 227-232
28. Rosenberg PA, Knowles R, Knowles KP, et al. Beta-adrenergic receptor-mediated regulation of extracellular adenosine in cerebral cortex in culture. J Neurosci 1994; 14: 2953-2965
29. Brundege JM, Diao L, Proctor WR, et al. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology 1997; 36: 1201-1210
30. Braun N, Lenz C, Gillardon F, et al. Focal cerebral ischemia enhances glial expression of ecto-5′-nucleotidase. Brain Res 1997; 766: 213-226
31. Lynch JJ, III, Alexander KM, Jarvis MF, et al. Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. Neurosci Lett 1998; 252: 207-210
32. Decking UK, Schlieper G, Kroll K, et al. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 1997; 81: 154-164
33. Kroll K, Decking UK, Dreikorn K, et al. Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart. Circ Res 1993; 73: 846-856
34. Pak MA, Haas HL, Decking UKM, et al. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology 1994; 33: 1049-1053
35. Geiger JD, Parkinson FE, Kowaluk EA. Regulators of endogenous adenosine levels as therapeutic agents. In: Jacobson KA, Jarvis MF, eds, Purinergic Approaches in Experimental Therapeutics, New York: Wiley-Liss, Inc., 1997, pp. 55-84
36. Sinclair CJ, Shepel PN, Geiger JD, et al. Stimulation of nucleoside efflux and inhibition of adenosine kinase by A1 adenosine receptor activation. Biochem Pharmacol 2000; 59: 477-483
37. Coe I, Zhang Y, McKenzie T, et al. PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett 2002; 517: 201-205
38. Chaudary N, Naydenova Z, Shuralyova I, et al. Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc Res 2004; 61: 780-788
39. Chaudary N, Naydenova Z, Shuralyova I, et al. The adenosine transporter, mENT1, is a target for adenosine receptor signaling and PKC{epsilon} in hypoxic and pharmacological preconditioning in the mouse cardiomyocyte cell line, HL-1. J Pharmacol Exp Ther 2004; 310: 1190-1198
40. Wang Y, White TD. Effect of protein kinase C activation on N-methyl-D-aspartate-evoked release of adenosine and [3H]Norepinephrine from rat cortical slices. J Pharmacol Exp Ther 1998; 285: 105-109
41. Eisenach JC, Hood DD, Curry R, et al. Intrathecal but not intravenous opioids release adenosine from the spinal cord. J Pain 2004; 5: 64-68
42. Sweeney MI, White TD, Sawynok J. Morphine-evoked release of adenosine from the spinal cord occurs via a nucleoside carrier with differential sensitivity to dipyridamole and nitrobenzylthioinosine [published erratum appears in Brain Res 1993; 618: 179]. Brain Res 1993; 614: 301-307
43. Sweeney MI, White TD, Sawynok J. Morphine-evoked release of adenosine from the spinal cord occurs via a nucleoside carrier with differential sensitivity to dipyridamole and nitrobenzylthioinosine [published erratum appears in Brain Res 1993; 618: 179]. Brain Res 1993; 614: 301-307
44. Craig CG, White TD. N-methyl-D-aspartate- and non-N-methyl-D-aspartate- evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J Neurochem 1993; 60: 1073-1080
45. Parkinson FE, Rudolphi KA, Fredholm BB. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen Pharmacol 1994; 25: 1053-1058
46. Farinelli SE, Greene LA, Friedman WJ. Neuroprotective actions of dipyridamole on cultured CNS neurons. J Neurosci 1998; 18: 5112-5123
47. Shuralyova I, Tajmir P, Bilan PJ, et al. Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole. Am J Physiol Heart Circ Physiol 2004; 286: H627-H632
48. Weishaar RE, Burrows SD, Kobylarz DC, et al. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol 1986; 35: 787-800
49. Iuliano L, Pedersen JZ, Rotilio G, et al. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 1995; 18: 239-247
50. Nakagawa Y, Gudenzi M, Mustafa SJ. Calcium entry blocking activity of dilazep and other adenosine potentiating compounds in guinea-pig atria. Eur J Pharmacol 1986; 122: 51-58
51. Nakamura K, Kojima K, Arai T, et al. Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Eur J Clin Invest 1998; 28: 877-883
52. Gati WP, Paterson AR. Measurement of nitrobenzylthioinosine in plasma and erythrocytes: a pharmacokinetic study in mice. Cancer Chemother Pharmacol 1997; 40: 342-346
53. Delaney SM, Geiger JD. Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. J Neurosci Meth 1996; 64: 151-156
54. Parkinson FE, Zhang YW, Shepel PN, et al. Effects of nitrobenzylthioinosine on neuronal injury, adenosine levels, and adenosine receptor activity in rat forebrain ischemia. J Neurochem 2000; 75: 795-802
55. Zhang YW, Shepel PN, Peeling J, et al. Effects of nitrobenzylthioinosine on neuronal injury and adenosine levels in rat forebrain ischemia. Neurosci Res Comm 2002; 30: 83-89
56. Anderson CM, Sitar DS, Parkinson FE. Ability of nitrobenzylthioinosine to cross the blood-brain barrier in rats. Neurosci Lett 1996; 219: 191-194
57. Phillis JW, O'Regan MH, Walter GA. Effects of two nucleoside transport inhibitors, dipyridamole and soluflazine, on purine release from the rat cerebral cortex. Brain Res 1989; 481: 309-316
58. Sollevi A. Cardiovascular effects of adenosine in man: possible clinical implications. Prog Neurobiol 1986; 27: 319-349
59. Parkinson FE, Xiong W. Stimulus- and cell-type-specific release of purines in cultured rat forebrain astrocytes and neurons. J Neurochem 2004; 88: 1305-1312